Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure

Trial Profile

GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bucindolol (Primary) ; Metoprolol succinate
  • Indications Atrial fibrillation; Atrial flutter; Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms GENETIC-AF; GENETIC-AF
  • Sponsors ARCA biopharma Inc
  • Most Recent Events

    • 11 Sep 2019 According to an ARCA biopharma media release, clinical data from this trial have been selected for presentation at the Heart Failure Society of America (HFSA) 2019 Annual Scientific Meeting (being held 13th-16th Sep 2019 in Philadelphia).William T. Abraham, MD, FACP, FACC, College of Medicine Distinguished Professor, Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, will present the data.
    • 13 May 2019 Results published in the ARCA biopharma media release.
    • 13 May 2019 According to an ARCA biopharma media release, data from this trial was published in the Journal of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top